




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

ImmuCell

IMMUCELL CORP DE
Rank 13 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

ImmuCell

IMMUCELL CORP DE Rank 13 of 50

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 165% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 355% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	16,265
Assets, Non-Current	1,135
General and Administrative Expense	14,817
Goodwill	172
Liabilities Hidden Reserves	0
Liabilities, Current	2,534
Liabilities, Non-Current	9,354
Other Assets	0
Other Compr. Net Income	0
Other Expenses	9.2
Other Liabilities	0
Other Net Income	-327
Property, Plant and Equipment, Net	26,894
Research and Development	4,169
Revenues	19,243

Output Variable	Value in 1000 USD
Liabilities	11,889
Assets	44,466
Expenses	18,995
Market Value Liabilities	11,889
Market Value Assets	44,466
Stockholders Equity	32,577
Net Income	-78
Comprehensive Net Income	-78
Economic Capital Ratio	126%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai